First oral SMA therapy will be delivered to patients’ homes, well placed for virtual launch

Evrysdi from Genentech, PTC is approved for children and adults, will be priced lower than other SMA drugs

FDA’s early approval on Friday of the first oral spinal muscular atrophy treatment, Evrysdi risdiplam, leaves Genentech and PTC well positioned for a virtual launch amidst COVID-19.

The Roche (SIX:ROG; OTCQX:RHHBY) unit will begin to directly deliver the liquid drug to patients’ homes within two weeks via the Accredo Health Group Inc. unit of Express Scripts Holding Co. (NASDAQ:ESRX).

While commercial launches were expected to be one of the biopharma

Read the full 692 word article

How to gain access

Continue reading with a
two-week free trial.